Optimizing Biologics Prior Auth in Utah for Specialty Medications

Navigating biologics prior auth in Utah presents unique challenges due to the state's payer landscape and specific operational patterns. Klivira provides an automated solution to accelerate approvals for high-cost specialty drugs.

For Utah-based clinics and health systems, managing prior authorizations for biologics across rheumatology, dermatology, and gastroenterology can be a significant administrative burden. The complexity stems from indication-specific criteria, step therapy, and biosimilar policies, impacting patient access and revenue cycles. Klivira streamlines this process, ensuring compliant and efficient submissions.

The Landscape of Biologics Prior Authorization in Utah

Biologics, including TNF inhibitors, IL-17/23, IL-6, and JAK inhibitors, represent a substantial share of high-cost specialty drug prior authorizations. In Utah, these workflows are shaped by the state's specific Medicaid managed care programs, diverse commercial payer footprints, and any state-level PA mandates, requiring a nuanced approach to submission and follow-up.

Key Challenges in Utah's Biologics PA Workflow

Utah providers face common hurdles in biologics PA, including stringent indication-specific criteria, evolving step therapy requirements, and payer-specific biosimilar substitution policies. Additionally, documenting screening requirements (e.g., TB, hepatitis) and managing periodic re-authorizations for chronic treatments adds layers of administrative complexity, often delaying patient access to critical therapies.

Klivira's Automated Biologics PA Workflow for Utah Providers

**Indication Classification:** Identifies the specialty and disease state from EMR diagnoses to align with payer criteria.
**Step Therapy Automation:** Pulls prior-line therapy history (e.g., csDMARDs for rheumatology, 5-ASA for IBD) to fulfill step therapy requirements.
**Biosimilar Substitution Routing:** Applies per-payer biosimilar mandates, ensuring compliance with preferred product lists.
**Screening Documentation:** Extracts and organizes necessary screening data (e.g., PPD or IGRA, hepatitis B/C status, immunization status) from FHIR-enabled EMRs.
**Periodic Re-authorization:** Manages typical 6/12-month re-authorization cycles, incorporating continuous disease activity and response documentation.
**Medical-vs-Pharmacy Benefit Routing:** Accurately routes prior authorizations based on whether the agent falls under medical or pharmacy benefits, depending on administration mode.

Addressing Utah's Payer Mix for Biologics

Klivira's platform connects to a wide array of payer portals and supports standard electronic prior authorization (ePA) channels like X12 278 and NCPDP SCRIPT. This comprehensive connectivity allows Utah clinics and health systems to efficiently manage biologics prior authorizations across the state's Medicaid managed care plans and various commercial insurers, reducing manual effort and accelerating turnaround times.

Seamless EMR Integration for Biologics PA

Our platform integrates directly with your EMR system, leveraging SMART on FHIR capabilities to securely extract necessary patient data. This includes diagnoses, lab results, prior therapy history, and screening documentation, minimizing data entry errors and ensuring that prior authorization requests for biologics are complete and accurate upon submission, reducing the likelihood of denials.

Frequently asked questions

How does Klivira handle step therapy requirements for biologics in Utah?

Klivira's automated workflow identifies and pulls prior-line therapy history directly from the EMR, such as csDMARDs for rheumatology or 5-ASA for IBD. This data is then used to automatically fulfill payer-specific step therapy requirements, streamlining the submission process.

Can Klivira manage biosimilar substitution policies specific to Utah payers?

Yes, Klivira applies per-payer biosimilar mandates to ensure compliance with specific substitution policies. Our system routes prior authorization requests based on which biosimilars must be tried first according to individual payer guidelines, minimizing potential denials.

What EMR data does Klivira use for biologics prior authorization?

Klivira leverages SMART on FHIR integration to extract critical data points from your EMR. This includes patient diagnoses, prior-line therapy history, screening documentation (e.g., TB, hepatitis status), immunization records, and continuous disease-activity or response documentation for re-authorizations.

Does Klivira support re-authorization for chronic biologic treatments?

Absolutely. Klivira's workflow includes robust support for periodic re-authorization cycles, typically every 6 or 12 months, for chronic biologic treatments. The system prompts for and incorporates continuous disease-activity and response documentation required by payers to secure ongoing approvals.

How does Klivira differentiate between medical and pharmacy benefits for biologics?

Klivira's system includes medical-vs-pharmacy benefit routing capabilities. It accurately determines the appropriate benefit channel for a prior authorization based on the specific biologic agent and its administration mode, ensuring correct submission and preventing delays caused by misrouting.